About ars pharmaceuticals inc - SPRY
ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.
SPRY At a Glance
ARS Pharmaceuticals, Inc.
11682 El Camino Real
San Diego, California 92130
| Phone | 1-858-771-9307 | Revenue | 84.28M | |
| Industry | Pharmaceuticals: Major | Net Income | -171,298,000.00 | |
| Sector | Health Technology | Employees | 158 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
SPRY Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 13.625 |
| Price to Book Ratio | 10.124 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -5.617 |
| Enterprise Value to Sales | 11.869 |
| Total Debt to Enterprise Value | 0.097 |
SPRY Efficiency
| Revenue/Employee | 533,405.063 |
| Income Per Employee | -1,084,164.557 |
| Receivables Turnover | 3.199 |
| Total Asset Turnover | 0.248 |
SPRY Liquidity
| Current Ratio | 7.278 |
| Quick Ratio | 7.064 |
| Cash Ratio | 6.258 |
SPRY Profitability
| Gross Margin | 75.767 |
| Operating Margin | -212.924 |
| Pretax Margin | -203.348 |
| Net Margin | -203.254 |
| Return on Assets | -50.47 |
| Return on Equity | -92.33 |
| Return on Total Capital | -81.099 |
| Return on Invested Capital | -73.294 |
SPRY Capital Structure
| Total Debt to Total Equity | 84.862 |
| Total Debt to Total Capital | 45.906 |
| Total Debt to Total Assets | 29.593 |
| Long-Term Debt to Equity | 84.348 |
| Long-Term Debt to Total Capital | 45.627 |